HC Wainwright started coverage on shares of Innate Pharma (NASDAQ:IPHYF) in a research note published on Wednesday, MarketBeat reports. The firm issued a buy rating on the stock.

Separately, Zacks Investment Research upgraded Innate Pharma from a sell rating to a hold rating in a research report on Tuesday, May 9th.

Shares of Innate Pharma (NASDAQ IPHYF) remained flat at $12.96 on Wednesday. Innate Pharma has a 52-week low of $10.72 and a 52-week high of $16.55. The firm has a 50-day moving average price of $12.56 and a 200 day moving average price of $12.41. The firm has a market cap of $699.74 million and a PE ratio of 48.18.

ILLEGAL ACTIVITY NOTICE: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/02/hc-wainwright-begins-coverage-on-innate-pharma-iphyf.html.

Receive News & Stock Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related stocks with our FREE daily email newsletter.